Bio Green Med Solution stock reports Q2 revenue of USD 336,000

Published on 10/07/2026 at 06:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bio Green Med Solution stock posted a USD 405,000 Q2 net loss on August 12, 2026. The October 6 close was USD 0.8557, down 1.46 percent.

BGMS, US23254L8761, Illustration mit AI erstellt.

Bio Green Med Solution (ISIN US23254L8761) reported USD 336,000 in second-quarter 2026 revenue, while its stock closed at USD 0.8557 on Nasdaq on October 6, 2026, down 1.46 percent. The latest operating figures show why the company's transition toward fire safety products remains central to the investment case.

Q2 revenue fell 56.8123 percent

According to Investing.com in its August 12, 2026 financial summary, revenue in the latest quarter was USD 336,000, compared with USD 778,000 in the prior quarter. That equals a 56.8123 percent sequential decline and is the clearest quantified pressure point in the Q2 update.

The same Investing.com summary lists an adjusted or reported EPS figure of negative USD 0.08 and a net loss of USD 405,000 for Q2 2026. The prior quarter showed a net loss of USD 197,000, so the loss widened alongside the revenue contraction.

Fire safety drives the business shift

Bio Green Med Solution is described by Stockanalysis.com as a supplier and installer of fire safety materials, equipment and prevention systems, with pharmaceutical research also part of the business. The company was formerly known as Cyclacel Pharmaceuticals and changed its name in September 2022.

The operating mix makes the revenue comparison more important than the biotechnology legacy alone. A lower Q2 revenue base of USD 336,000 leaves limited room for execution slippage, while the USD 405,000 quarterly loss shows that cost absorption remains a material issue for shareholders.

Stock sits 87.23 percent below high

At USD 0.8557, the Nasdaq-listed stock stood 87.23 percent below its 52-week high of USD 6.7000 and 51.08 percent above its 52-week low of USD 0.5664 on October 6, 2026. Its market capitalization was USD 5.7 million on that date, placing the Q2 revenue trend in the context of a very small equity value.

For investors, the key comparison is therefore operational rather than speculative: Q2 revenue declined from USD 778,000 to USD 336,000, while the net loss increased from USD 197,000 to USD 405,000. The next valuation discussion depends on whether fire safety activity can rebuild revenue faster than operating costs.

Nasdaq close sets the reference point

Bio Green Med Solution stock closed at USD 0.8557 on Nasdaq on October 6, 2026, with a daily change of negative 1.46 percent. The company has 12 employees, according to Stockanalysis.com, underscoring the scale of the business behind the listed security.